A promising drug controlled-release system based on diacetylene/ phospholipid polymerized vesicles

Caixin Guo, Shaoqin Liu, Chang Jiang, Wenyuan Li, Zhifei Dai, Hiroe Fritz, Xiaoyi Wu

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A novel polymerized vesicular carrier loaded with paclitaxel was developed by introducing the ultraviolet (UV) crosslinkable 10,12-pentacosadiynoic acid (PCDA) into bilayered phospholipid vesicles with the purpose of improving the physicochemical stability as well as the controlled-release property of liposomes. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) results revealed the enhanced stability of PCDA-polymerized vesicles against Triton X-100. In particular, alteration in PCDA/phospholipids ratios and UV-irradiation time can modulate the cumulative paclitaxel released. For instance, vesicles composed of phospholipids only released 98.0 ± 2.1 % of paclitaxel within 24 h. Over the same time period, 72.0 ± 5.8%, 43.9 ± 6.5%, and 20.1 ± 5.4% of paclitaxel was released from polymerized PCDA/phospholipid vesicles at molar ratios of 1:3,1:1, and 3:1, respectively. Likewise, by increasing the UV-irradiation time from 20 to 40 min, the cumulative release of paclitaxel from polymerized PCDA/phospholipid vesicles at molar ratio of 1:1 decreased from 90.5 ± 3.7% to 37.6 ± 2.3% over a time period of experimental observation of 24 h. The influences of vesicle composition (i.e., PCDA/phospholipids ratio) and UV-irradiation time on the release rates of paclitaxel were further examined by finite element (FE) analyzed using Abaqus. Our results demonstrate that novel polymerized vesicles capable of regulating the release of anticancer drugs such as paclitaxel have been developed.

Original languageEnglish (US)
Pages (from-to)13114-13119
Number of pages6
JournalLangmuir
Volume25
Issue number22
DOIs
StatePublished - Nov 17 2009

Fingerprint

Phospholipids
Paclitaxel
drugs
acids
Acids
Pharmaceutical Preparations
Irradiation
irradiation
Liposomes
light transmission
Dynamic light scattering
Light transmission
Octoxynol
light scattering
12-pentacosadiynoic acid 10
Transmission electron microscopy
transmission electron microscopy
Chemical analysis

ASJC Scopus subject areas

  • Electrochemistry
  • Condensed Matter Physics
  • Surfaces and Interfaces
  • Materials Science(all)
  • Spectroscopy

Cite this

A promising drug controlled-release system based on diacetylene/ phospholipid polymerized vesicles. / Guo, Caixin; Liu, Shaoqin; Jiang, Chang; Li, Wenyuan; Dai, Zhifei; Fritz, Hiroe; Wu, Xiaoyi.

In: Langmuir, Vol. 25, No. 22, 17.11.2009, p. 13114-13119.

Research output: Contribution to journalArticle

Guo, Caixin ; Liu, Shaoqin ; Jiang, Chang ; Li, Wenyuan ; Dai, Zhifei ; Fritz, Hiroe ; Wu, Xiaoyi. / A promising drug controlled-release system based on diacetylene/ phospholipid polymerized vesicles. In: Langmuir. 2009 ; Vol. 25, No. 22. pp. 13114-13119.
@article{d4638b06e9c240c78fb4807cf102fcc6,
title = "A promising drug controlled-release system based on diacetylene/ phospholipid polymerized vesicles",
abstract = "A novel polymerized vesicular carrier loaded with paclitaxel was developed by introducing the ultraviolet (UV) crosslinkable 10,12-pentacosadiynoic acid (PCDA) into bilayered phospholipid vesicles with the purpose of improving the physicochemical stability as well as the controlled-release property of liposomes. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) results revealed the enhanced stability of PCDA-polymerized vesicles against Triton X-100. In particular, alteration in PCDA/phospholipids ratios and UV-irradiation time can modulate the cumulative paclitaxel released. For instance, vesicles composed of phospholipids only released 98.0 ± 2.1 {\%} of paclitaxel within 24 h. Over the same time period, 72.0 ± 5.8{\%}, 43.9 ± 6.5{\%}, and 20.1 ± 5.4{\%} of paclitaxel was released from polymerized PCDA/phospholipid vesicles at molar ratios of 1:3,1:1, and 3:1, respectively. Likewise, by increasing the UV-irradiation time from 20 to 40 min, the cumulative release of paclitaxel from polymerized PCDA/phospholipid vesicles at molar ratio of 1:1 decreased from 90.5 ± 3.7{\%} to 37.6 ± 2.3{\%} over a time period of experimental observation of 24 h. The influences of vesicle composition (i.e., PCDA/phospholipids ratio) and UV-irradiation time on the release rates of paclitaxel were further examined by finite element (FE) analyzed using Abaqus. Our results demonstrate that novel polymerized vesicles capable of regulating the release of anticancer drugs such as paclitaxel have been developed.",
author = "Caixin Guo and Shaoqin Liu and Chang Jiang and Wenyuan Li and Zhifei Dai and Hiroe Fritz and Xiaoyi Wu",
year = "2009",
month = "11",
day = "17",
doi = "10.1021/la9034112",
language = "English (US)",
volume = "25",
pages = "13114--13119",
journal = "Langmuir",
issn = "0743-7463",
publisher = "American Chemical Society",
number = "22",

}

TY - JOUR

T1 - A promising drug controlled-release system based on diacetylene/ phospholipid polymerized vesicles

AU - Guo, Caixin

AU - Liu, Shaoqin

AU - Jiang, Chang

AU - Li, Wenyuan

AU - Dai, Zhifei

AU - Fritz, Hiroe

AU - Wu, Xiaoyi

PY - 2009/11/17

Y1 - 2009/11/17

N2 - A novel polymerized vesicular carrier loaded with paclitaxel was developed by introducing the ultraviolet (UV) crosslinkable 10,12-pentacosadiynoic acid (PCDA) into bilayered phospholipid vesicles with the purpose of improving the physicochemical stability as well as the controlled-release property of liposomes. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) results revealed the enhanced stability of PCDA-polymerized vesicles against Triton X-100. In particular, alteration in PCDA/phospholipids ratios and UV-irradiation time can modulate the cumulative paclitaxel released. For instance, vesicles composed of phospholipids only released 98.0 ± 2.1 % of paclitaxel within 24 h. Over the same time period, 72.0 ± 5.8%, 43.9 ± 6.5%, and 20.1 ± 5.4% of paclitaxel was released from polymerized PCDA/phospholipid vesicles at molar ratios of 1:3,1:1, and 3:1, respectively. Likewise, by increasing the UV-irradiation time from 20 to 40 min, the cumulative release of paclitaxel from polymerized PCDA/phospholipid vesicles at molar ratio of 1:1 decreased from 90.5 ± 3.7% to 37.6 ± 2.3% over a time period of experimental observation of 24 h. The influences of vesicle composition (i.e., PCDA/phospholipids ratio) and UV-irradiation time on the release rates of paclitaxel were further examined by finite element (FE) analyzed using Abaqus. Our results demonstrate that novel polymerized vesicles capable of regulating the release of anticancer drugs such as paclitaxel have been developed.

AB - A novel polymerized vesicular carrier loaded with paclitaxel was developed by introducing the ultraviolet (UV) crosslinkable 10,12-pentacosadiynoic acid (PCDA) into bilayered phospholipid vesicles with the purpose of improving the physicochemical stability as well as the controlled-release property of liposomes. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) results revealed the enhanced stability of PCDA-polymerized vesicles against Triton X-100. In particular, alteration in PCDA/phospholipids ratios and UV-irradiation time can modulate the cumulative paclitaxel released. For instance, vesicles composed of phospholipids only released 98.0 ± 2.1 % of paclitaxel within 24 h. Over the same time period, 72.0 ± 5.8%, 43.9 ± 6.5%, and 20.1 ± 5.4% of paclitaxel was released from polymerized PCDA/phospholipid vesicles at molar ratios of 1:3,1:1, and 3:1, respectively. Likewise, by increasing the UV-irradiation time from 20 to 40 min, the cumulative release of paclitaxel from polymerized PCDA/phospholipid vesicles at molar ratio of 1:1 decreased from 90.5 ± 3.7% to 37.6 ± 2.3% over a time period of experimental observation of 24 h. The influences of vesicle composition (i.e., PCDA/phospholipids ratio) and UV-irradiation time on the release rates of paclitaxel were further examined by finite element (FE) analyzed using Abaqus. Our results demonstrate that novel polymerized vesicles capable of regulating the release of anticancer drugs such as paclitaxel have been developed.

UR - http://www.scopus.com/inward/record.url?scp=71549127446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549127446&partnerID=8YFLogxK

U2 - 10.1021/la9034112

DO - 10.1021/la9034112

M3 - Article

C2 - 19852472

AN - SCOPUS:71549127446

VL - 25

SP - 13114

EP - 13119

JO - Langmuir

JF - Langmuir

SN - 0743-7463

IS - 22

ER -